Evotec (EVO) Stock: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$1.61
0.03 (2.23%)
â˛
5d:
+2.88%
30d:
-2.13%
90d:
-16.84%
WAIT
LOW Confidence
Analysis Updated: Oct 28, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At -4.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At -4.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $1.60, which is considered slightly high relative to its 30-day fair value range of $1.45 to $1.63. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.9) compared to its historical average (26.2). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVO is in a strong downtrend. The price is approaching resistance at $1.61. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.20 (+161.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVO is in a strong downtrend. The price is approaching resistance at $1.61. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.20 (+161.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.45 -
$1.63
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 161.5% below Wall St target ($4.20)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.45 -
$1.63
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.38
Resistance Level
$1.61
Current Trend
Strong Downtrend
Technical data as of
Oct 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.93
Wall Street Target
$4.20
(+161.5%)
Revenue Growth (YoY)
-16.2%
Profit Margin
-27.5%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
22.9 vs 26.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$1.53
(-4%)
2-Year Target
$1.47
(-9%)
3-Year Target
$1.40
(-13%)
3-Yr Target (if PE normalizes)
(PE: 23â26)
$1.60
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.9 to 26.2
Stabilization Target:
$1.83
(+14.3%)
PE Expansion Potential:
+14.3%
Share & Embed Analysis
Last updated: October 28, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$206 | 46 HOLD |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 62 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$30 | 52 HOLD |
|
TEVA
Teva Pharma Industries LâĻ |
STRONG BUY
13 analysts |
$48 | 56 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$56 | 36 SELL |
